Vinorelbine With Pertuzumab and Trastuzumab as First-Line Treatment in Patients With HER2-Positive Breast Cancer

Pertuzumab and trastuzumab given with a taxane is recommended by NCCN guidelines for the first-line treatment of patients with HER2-positive metastatic breast cancer. This recommendation is largely based on the CLEOPATRA study, which demonstrated a PFS and OS advantage to adding pertuzumab.

 Practice Update